ATE412756T1 - Verfahren zur krebsdiagnose mittels eines chimärischen toxin - Google Patents

Verfahren zur krebsdiagnose mittels eines chimärischen toxin

Info

Publication number
ATE412756T1
ATE412756T1 AT99910652T AT99910652T ATE412756T1 AT E412756 T1 ATE412756 T1 AT E412756T1 AT 99910652 T AT99910652 T AT 99910652T AT 99910652 T AT99910652 T AT 99910652T AT E412756 T1 ATE412756 T1 AT E412756T1
Authority
AT
Austria
Prior art keywords
chimeric toxin
diagnosing cancer
gnrh
relates
chimeric
Prior art date
Application number
AT99910652T
Other languages
English (en)
Inventor
Haya Lorberboum-Galski
Ami Ben-Yehudah
Amotz Nechushtan
Shai Yarkoni
Irina Marianovsky
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE412756T1 publication Critical patent/ATE412756T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99910652T 1998-03-24 1999-03-24 Verfahren zur krebsdiagnose mittels eines chimärischen toxin ATE412756T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/046,992 US6140066A (en) 1998-03-24 1998-03-24 Methods of cancer diagnosis using a chimeric toxin

Publications (1)

Publication Number Publication Date
ATE412756T1 true ATE412756T1 (de) 2008-11-15

Family

ID=21946472

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99910652T ATE412756T1 (de) 1998-03-24 1999-03-24 Verfahren zur krebsdiagnose mittels eines chimärischen toxin

Country Status (10)

Country Link
US (1) US6140066A (de)
EP (1) EP1066390B1 (de)
CN (1) CN1303438A (de)
AT (1) ATE412756T1 (de)
AU (1) AU758839B2 (de)
CA (1) CA2323786A1 (de)
DE (1) DE69939819D1 (de)
IL (1) IL138655A0 (de)
NZ (1) NZ507294A (de)
WO (1) WO1999049059A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US7314632B1 (en) 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
ES2249838T3 (es) * 1997-07-11 2006-04-01 The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services Inmunogenos quimericos similares a la exotoxina a de pseudomonas.
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2003007889A2 (en) * 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
CN1683416A (zh) * 2004-04-13 2005-10-19 李相哲 高效低毒的系列功能蛋白
CN100379869C (zh) * 2004-08-09 2008-04-09 生宝生物科技股份有限公司 超抗原融合蛋白及其应用方法
CN1768862A (zh) * 2004-10-26 2006-05-10 北京诺思兰德生物技术有限责任公司 一类能与表达GnRH受体的癌细胞特异结合且用锝－99m标记的蛋白
EP1855724A2 (de) * 2005-02-01 2007-11-21 Research Development Foundation Blys-fusionsproteine für targeting des blys-rezeptors und verfahren zur behandlung von proliferativen b-zell-störungen
KR100808735B1 (ko) 2006-11-04 2008-02-28 진은철 황체호르몬 분비호르몬 및 독소분자의 복합체를유효성분으로 하는 건선 예방 및 치료제
CN101195822B (zh) * 2006-12-08 2012-08-08 湖南康都制药有限公司 高亲和性靶向融合蛋白
CN101343328B (zh) * 2008-08-25 2011-06-01 北京博翱泰生物技术有限公司 靶特异性双突变体融合蛋白质
CN103864938A (zh) * 2014-03-24 2014-06-18 北京博翱泰生物技术有限公司 靶特异性双突变体融合蛋白质及其制备工艺
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012173A1 (en) * 1991-01-04 1992-07-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce A method for constructing antigens
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma

Also Published As

Publication number Publication date
US6140066A (en) 2000-10-31
NZ507294A (en) 2003-05-30
CA2323786A1 (en) 1999-09-30
WO1999049059A2 (en) 1999-09-30
DE69939819D1 (de) 2008-12-11
AU2955199A (en) 1999-10-18
EP1066390A2 (de) 2001-01-10
AU758839B2 (en) 2003-04-03
WO1999049059A3 (en) 1999-12-02
IL138655A0 (en) 2001-10-31
CN1303438A (zh) 2001-07-11
EP1066390B1 (de) 2008-10-29

Similar Documents

Publication Publication Date Title
ATE412756T1 (de) Verfahren zur krebsdiagnose mittels eines chimärischen toxin
PE20050712A1 (es) Anticuerpos rg1
EP0914155A4 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DE69936049D1 (de) Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ATE403001T1 (de) Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
NO985120D0 (no) Monoklonalt antistoff mot CEA, konjugater omfattende nevnte antistoff og deres terapeutiske anvendelse i et adeptsystem
ECSP024210A (es) Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas
EP2196474A3 (de) Therapeutische Zielmolekulen in Krebs
EP2502937A3 (de) Anti-CD 79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
WO2004032857A3 (en) Antibody therapy
EA200800094A1 (ru) Антитела cd19 и их использование
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
DE69839123D1 (de) Prostattumor polynukleotid- und antigenzusammensetzungen
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
MXPA04003508A (es) Anticuerpos humanos que se unen a mn.
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
UY26170A1 (es) Antigeno (c42) asociados a tumores
DE60333820D1 (de) Konjugate mit einem für die ed-b-domäne von fibronectin spezifischen antikörper, und deren verwendung zum nachweis und zur behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties